{
  "id": "subunit-vaccine",
  "title": "Subunit Vaccine",
  "lang": "en",
  "source_lang": "en",
  "summary": "A subunit vaccine induces immunity using selected components of a pathogen rather than the complete organism.",
  "category": "health",
  "subcategory": "drugs",
  "type": "concept",
  "aliases": [
    "Subunit-based vaccine"
  ],
  "generated_at": "2026-11-03",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/subunit-vaccine/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/subunit-vaccine/",
      "json": "https://aiwiki.page/zh/subunit-vaccine.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "A subunit vaccine is a vaccine that contains selected components of a pathogen rather than the complete organism. These components, called antigens, stimulate the immune system to recognize a target associated with infection. They may include proteins, bacterial surface sugars, or structures assembled from these molecules. Because subunit vaccines do not contain a complete, replication-capable pathogen, they cannot cause infection by that pathogen. Their effectiveness and safety nevertheless depend on the particular antigen, formulation, dose, and population."
    },
    {
      "heading": "Definition and classification",
      "text": "“Subunit” describes the material delivered in a vaccine, not a single manufacturing method. Antigens may be purified from a cultured organism, produced through recombinant technology, or synthesized chemically.\n\nThe term is used at different levels of breadth:\n\n- Protein subunit vaccines contain one or more selected pathogen proteins or protein fragments.\n- Polysaccharide vaccines contain purified sugar molecules, usually from bacterial capsules.\n- Conjugate vaccines contain a polysaccharide chemically attached to a carrier protein.\n- Virus-like particle vaccines contain proteins assembled into particles resembling a virus but lacking the viral genome required for replication.\n\nSome classifications group these together as subunit vaccines; others list polysaccharide, conjugate, and virus-like particle vaccines separately. Vaccines made from detoxified bacterial toxins, known as toxoids, are also commonly treated as a distinct category, although they likewise use a selected pathogen-derived component.\n\nA subunit vaccine differs from a live attenuated vaccine, which contains a weakened organism capable of limited replication, and from a whole-organism inactivated vaccine, which contains killed or otherwise inactivated pathogens. Unlike nucleic acid vaccines and many viral vector vaccines, a subunit vaccine supplies the antigen itself rather than genetic instructions for producing it inside the recipient’s cells."
    },
    {
      "heading": "How it produces immunity",
      "text": "Antigen recognition and immune memory\n\nThe selected antigen exposes molecular features that the immune system can recognize. B cells that recognize these features can develop into cells that produce antibodies. Depending on the target, these antibodies may prevent a virus from entering cells, neutralize a toxin, or help immune cells eliminate bacteria.\n\nFor protein antigens, antigen-presenting cells process the protein and display peptide fragments to T cells. Helper T cells support antibody production, antibody affinity maturation, and the development of immune memory. Memory cells can then respond more rapidly after a later encounter with the pathogen.\n\nPurified protein vaccines generally favor antibody and helper T-cell responses. They often stimulate cytotoxic T-cell responses less efficiently than platforms that produce antigen inside cells, although antigen design and delivery systems can alter this pattern.\n\nAdjuvants and repeated doses\n\nIsolated antigens may lack the signals that accompany a natural infection. Many subunit vaccines therefore contain a vaccine adjuvant, which enhances or shapes the immune response. Adjuvants may improve antigen delivery, stimulate innate immune recognition, or promote activation of antigen-presenting cells.\n\nSeveral doses may be needed to establish an adequate response, and some products use later booster doses. These requirements are product-specific: neither the need for an adjuvant nor a particular dosing schedule follows automatically from the label “subunit vaccine.”"
    },
    {
      "heading": "Major forms",
      "text": "Protein subunit vaccines\n\nProtein subunit vaccines use selected proteins associated with a pathogen’s surface, attachment machinery, or other biologically important structures. Some contain a single antigen; others combine multiple antigens to broaden coverage.\n\nProteins may be purified directly from pathogen cultures or produced by recombinant methods. In recombinant production, a gene encoding the antigen is introduced into a suitable production system, such as yeast, insect cells, or mammalian cells. The resulting protein is harvested, purified, and formulated.\n\n“Recombinant” and “subunit” are therefore not synonyms. The former describes a production method; the latter describes the vaccine’s antigenic composition.\n\nPolysaccharide vaccines\n\nSome bacteria possess an outer capsule made of polysaccharides. Antibodies directed against these capsule components can contribute to protection.\n\nUnconjugated polysaccharides typically stimulate B cells without substantial helper T-cell involvement. This produces a different immune response from that induced by proteins: immune memory is generally limited, and responses are often poor in children younger than about two years. Protection can also be restricted to the capsule types represented in the vaccine.\n\nConjugate vaccines\n\nA conjugate vaccine links a polysaccharide antigen to a carrier protein. A B cell recognizing the polysaccharide can take up the conjugate and present fragments of the carrier protein to helper T cells. This recruits T-cell help for the response against the polysaccharide.\n\nConjugation enables effective responses in infancy and supports immune memory. The carrier protein’s role is immunological; it does not necessarily mean that the product also provides adequate protection against the disease associated with that carrier.\n\nVirus-like particles\n\nA virus-like particle is a self-assembled structure made from viral proteins without a functional viral genome. Its repetitive surface arrangement can efficiently engage B cells while preserving important antigenic shapes.\n\nVirus-like particle vaccines overlap with the protein subunit category, although their organized particulate structure distinguishes them from formulations containing soluble proteins."
    },
    {
      "heading": "Development and applications",
      "text": "An early hepatitis B vaccine, licensed in the United States in 1981, used surface antigen purified from human plasma. A recombinant hepatitis B vaccine was licensed in the United States in 1986, establishing a major application of recombinant antigen production.\n\nSubunit approaches are now used against several infections:\n\nTarget | Subunit approach\n[[hepatitis-b | Hepatitis B]]\n[[human-papillomavirus-infection | Human papillomavirus infection]]\nPertussis | Acellular vaccines containing selected, purified bacterial antigens\nPneumococcal, meningococcal, and Haemophilus influenzae type b disease | Capsular polysaccharides, either unconjugated or protein-conjugated, depending on the product\nShingles | Recombinant varicella-zoster virus glycoprotein formulated with an adjuvant\n[[covid-19 | COVID-19]]\n[[malaria | Malaria]]\n\nThese products do not share a single level or duration of protection. Their effects on infection, symptomatic illness, severe disease, and transmission must be assessed separately."
    },
    {
      "heading": "Antigen design and manufacturing",
      "text": "Antigen selection requires identifying components that induce protective immunity rather than merely a detectable immune response. Antibodies against one region of a pathogen may block infection, whereas antibodies against another region may bind without providing substantial protection.\n\nManufacturing must preserve relevant antigenic structures. Protein folding, chemical modifications, particle assembly, and stability can all affect immune recognition. A production system that generates large quantities of protein is not necessarily suitable if the protein adopts the wrong shape.\n\nQuality control includes assessment of antigen identity, purity, potency, consistency, and stability, as well as control of residual production materials. Subunit vaccines avoid the need to include a complete pathogen in the finished product, but their production can still be technically demanding. Refrigeration and other storage requirements vary by formulation; subunit vaccines are not inherently heat-stable."
    },
    {
      "heading": "Advantages and limitations",
      "text": "Advantages\n\nThe absence of a replication-capable pathogen eliminates the possibility of vaccine-strain infection from the target organism. This is an important distinction from live vaccines, particularly in the context of immunodeficiency.\n\nA defined antigen composition also allows developers to focus responses on selected targets, combine antigens, and modify components without necessarily changing the entire production platform.\n\nLimitations\n\nA narrow antigen selection can limit protection if the pathogen varies substantially or if important protective targets have been omitted. Changes in antigen structure may also reduce recognition by existing immune responses.\n\nOther limitations can include:\n\n- A need for adjuvants or multiple doses.\n- Waning protection requiring product-specific booster schedules.\n- Limited mucosal or cytotoxic T-cell immunity with some formulations.\n- Manufacturing difficulties involving protein structure, yield, or stability.\n- Incomplete coverage of bacterial serotypes or pathogen variants.\n\nA strong antibody response in laboratory testing does not automatically establish clinical protection. Where a validated immune correlate of protection is unavailable, efficacy must be demonstrated through clinical outcomes."
    },
    {
      "heading": "Safety and evaluation",
      "text": "Subunit vaccines cannot reproduce the target pathogen, but they are not free of adverse effects. Depending on the product, reactions can include injection-site pain, fever, fatigue, or other transient systemic symptoms. Severe allergic reactions, including anaphylaxis, can occur rarely. Safety findings apply to particular products and formulations, not uniformly to the entire category.\n\nEvaluation through a clinical trial considers immune responses, clinical efficacy, and adverse events in the intended population. After authorization, pharmacovigilance and effectiveness studies help identify uncommon adverse events, assess the duration of protection, and characterize performance in populations that may have been underrepresented in initial trials."
    }
  ],
  "links": [
    "vaccine",
    "antigen",
    "immune-system",
    "live-attenuated-vaccine",
    "inactivated-vaccine",
    "viral-vector-vaccine",
    "b-cell",
    "antibody",
    "t-cell",
    "vaccine-adjuvant",
    "protein",
    "gene",
    "bacteria",
    "conjugate-vaccine",
    "hepatitis-b",
    "human-papillomavirus-infection",
    "covid-19",
    "malaria",
    "immunodeficiency",
    "fever",
    "anaphylaxis",
    "clinical-trial",
    "pharmacovigilance"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}